<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of nontuberculous mycobacterial infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of nontuberculous mycobacterial infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of nontuberculous mycobacterial infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David E Griffith, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mycobacteria other than <em>Mycobacterium tuberculosis</em> and <em>Mycobacterium leprae</em> are generally free-living organisms that are ubiquitous in the environment (<a class="graphic graphic_table graphicRef61936" href="/d/graphic/61936.html" rel="external">table 1</a>). They have been recovered from surface water, tap water, soil, domestic and wild animals, milk, and food products. Although nontuberculous mycobacteria (NTM) can inhabit body surfaces and secretions without causing disease, they can, in broad terms, induce four distinct clinical syndromes. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive pulmonary disease is usually associated with bronchiectasis or chronic obstructive lung disease and is primarily caused by <em>Mycobacterium avium</em> complex (MAC) <em>Mycobacterium kansasii</em> and <em>Mycobacterium abscessus</em>, especially in older persons.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superficial lymphadenitis, especially cervical lymphadenitis, in children is mostly caused by MAC, <em>Mycobacterium scrofulaceum</em>, and, in northern Europe, <em>Mycobacterium malmoense</em> (<em>M. tuberculosis</em> is a more common cause of lymphadenitis in tuberculosis-endemic countries).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated disease can occur in severely immunocompromised patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin and soft tissue infections usually are a consequence of direct inoculation. </p><p></p><p>The pathogenesis of NTM infections will be discussed here. An overview of NTM infections in patients with and without human immunodeficiency virus (HIV), as well as the microbiology, epidemiology, diagnosis, and treatment of NTM infections are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/3705.html" rel="external">"Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a> and  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a> and  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PULMONARY INFECTION</span><span class="headingEndMark"> — </span>The pathogenesis of lung disease due to nontuberculous mycobacteria (NTM) is poorly understood. Pulmonary infection with NTM is probably acquired by inhalation, most likely aerosols from natural surface water or from domestic and institutional hot water systems. Gastroesophageal reflux has been associated with MAC lung disease, raising the possibility that initial acquisition may be through ingestion with subsequent aspiration from the stomach [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a>.) </p><p>Comparative studies with tuberculosis (TB) in the pre-HIV era established that the granulomatous lesions caused by different species of mycobacteria were indistinguishable to trained pathologists [<a href="#rid3">3,4</a>]. Therefore, it is presumed that there are substantial similarities to the pathogenesis of TB.</p><p class="headingAnchor" id="H3"><span class="h2">Mycobacterium avium complex</span><span class="headingEndMark"> — </span>The observation that pulmonary <em>M. avium</em> complex (MAC) disease is relatively rare, despite the high prevalence of skin test reactivity to MAC in young adulthood [<a href="#rid5">5</a>], suggests that the host immune response is highly effective at containing or eliminating the infecting microbes. Both age and preexisting lung disease or lung injury are major risk factors for active NTM lung disease. </p><p class="headingAnchor" id="H784421222"><span class="h3">Cellular response</span><span class="headingEndMark"> — </span>If inhaled, MAC encounters alveolar macrophages. Macrophages bind to MAC through fibronectin receptors, receptors for mannosyl and fucosyl moieties of the mycobacterial cell wall, and complement components such as C3b and C4b [<a href="#rid6">6,7</a>]. Thus, serum enhances phagocytosis of mycobacteria through complement bound to the mycobacterial surface [<a href="#rid8">8</a>]. The multiple pathways by which NTM are able to enter macrophages suggest that the intracellular niche is a favorable adaption for the bacilli if the phagocytes are not primed to kill the bacteria. Bound mycobacteria are taken up in primary phagosomes that fuse with vacuoles in the phagocyte’s cytoplasm and attempt to destroy its contents through acidification, toxic oxygen metabolites, defensins (in neutrophils, small protein molecules that disrupt the bacterial cell wall), and possibly other mechanisms [<a href="#rid9">9,10</a>]. In general terms, MAC is taken up by macrophages and survives and proliferates within vacuoles in their cytoplasm as an intracellular pathogen. Immune-evasion mechanisms by which NTM are able to survive within macrophages include inhibition of phagosome-lysosome fusion, shift in metabolism to a more anaerobic intracellular environment, induction of NTM-related genes that enhance replication, direct inhibition of host macrophage function and lymphocyte proliferation, and possibly through induction of macrophage apoptosis by downregulation of the Bcl-2 gene product that normally inhibits apoptosis [<a href="#rid11">11-15</a>]. </p><p>Macrophages also process mycobacterial antigens and present them on their surface in conjunction with MHC class I and class II molecules to T lymphocytes. This results in tremendous expansion of T lymphocyte clones that specifically recognize those antigens and forms the basis of both acquired immune responses and immunologic memory that are central to host defense against mycobacteria. This process is exemplified by the delayed hypersensitivity response elicited by the <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a>. T helper (CD4) lymphocytes recruited to the site of mycobacterial infection secrete IL-2 and interferon gamma that activate macrophages and enhance cytotoxic lymphocyte activity [<a href="#rid7">7</a>]. (See <a class="local">'Role of cytokines'</a> below.)</p><p>If inhaled, MAC survive their initial encounter with alveolar macrophages blood-borne host defenses, lymphocytes and monocytes that differentiate into macrophages are recruited. Lymphocytes ultimately interact with the infected macrophages to induce intracellular destruction of the mycobacteria or to destroy the infected macrophage itself. T helper lymphocytes are the basis of acquired (antigen-specific) immunity, while natural killer (NK) cells are key components of the innate immune response for these pathogens. NK cells are lymphocytes that destroy certain neoplastic or infected cells, targeting cells with a paucity of major histocompatibility complex (MHC) class I surface molecules [<a href="#rid16">16</a>]. </p><p>These dynamic cellular events are mirrored histopathologically in the formation of granulomas in which infected foci become surrounded by mononuclear inflammatory cells and epithelioid histiocytes. However, the release of cytolytic enzymes and other cytotoxic proteins ultimately may result in the necrosis and encapsulating fibrosis of both infected and adjacent tissues [<a href="#rid17">17</a>]. These events lead to two major forms of pulmonary MAC disease in adults, the fibrocavitary and fibronodular forms described below. (See <a class="local">'Fibrocavitary disease'</a> below and <a class="local">'Nodular/bronchiectatic disease'</a> below.)</p><p>Furthermore, in one study evaluating the response of mouse monocytes exposed to MAC, heme oxygenase-1 (HO-1) was found to be important for monocyte chemoattractant protein-1 (MCP-1) trafficking, which is necessary for granuloma formation and containment of mycobacterial infection [<a href="#rid18">18</a>]. Well-formed lung granulomas are characteristic of pulmonary NTM disease, whereas patients with disseminated NTM disease associated with immune dysfunction have poorly formed granulomatous inflammation [<a href="#rid19">19</a>]. (See <a class="local">'Disseminated disease in HIV-infected patients'</a> below.)</p><p>Neutrophils have traditionally been viewed as relatively unimportant in defense against mycobacteria. For example, in one study, it was found that human neutrophils released less superoxide anion in response to <em>M. abscessus</em> than to <em>Staphylococcus aureus</em> [<a href="#rid20">20</a>]. Mycobacteria may exploit a neutrophil-rich setting to promote its survival.</p><p>This chain of events is presumably similar to that described for tuberculosis; although, in contrast to tuberculosis, a reliable animal model for evaluating nontuberculous mycobacterial disease pathogenesis has not yet been developed. It is not yet known if NTM infection leads to latent infection that later causes reactivation disease or if most NTM lung disease is the result of primary infection.</p><p class="headingAnchor" id="H784421228"><span class="h3">Role of cytokines</span><span class="headingEndMark"> — </span>Macrophages elaborate cytokines and other chemical messengers that recruit lymphocytes and other macrophages to the site of the infection, leading to complex interactions between these cell types that enhance killing of these microorganisms. Interleukin-12 (IL-12), tumor necrosis factor-alpha (TNFa), and interferon (IFN) gamma are especially important in the antimycobacterial immune response.</p><p>Macrophages that phagocytose mycobacteria respond with production of IL-12 [<a href="#rid21">21</a>], which activates T lymphocytes, and NK cells [<a href="#rid22">22,23</a>]. The NK cells respond to intracellular and extracellular MAC and are stimulated by IL-2, IL-12, and TNFa to release granules containing cytotoxic enzymes that lyse infected cells and also to secrete TNFa and IFN-gamma, which augment macrophage mycobactericidal capacity [<a href="#rid16">16,24,25</a>].</p><p>Binding of IL-12 results in the transcription of IL-12 responsive genes, in particular IFN-gamma. IFN-gamma activates neutrophils and macrophages to produce superoxide and nitric oxide, increases surface display of MHC molecules and Fc receptors, decreases lysosomal pH, and increases the intracellular concentration of certain antibiotics [<a href="#rid26">26-28</a>]. IFN-gamma signals ultimately influence IFN-gamma responsive genes such as IL-12, MHC genes, and TNFa [<a href="#rid27">27,29</a>]. The positive feedback loop between IFN-gamma and IL-12 is pivotal in the immune response to mycobacteria. Defects in any of these receptors or cytokine genes may negatively affect the production of IFN-gamma and/or IL-12 and, consequently, enhance mycobacterial susceptibility [<a href="#rid30">30</a>].</p><p>The importance of this pathway in susceptibility to infection due to otherwise poorly pathogenic mycobacteria (non-tuberculous mycobacteria or <em>Mycobacterium bovis</em> BCG) is borne out in genetic studies of patients with severe infections due to these organisms [<a href="#rid31">31</a>]. Many of these patients are unable to produce or respond to IFN-gamma due to mutations in genes that encode major proteins in the type 1 cytokine pathway. Similarly, in studies of adults of Asian origin, disseminated nontuberculous mycobacterial infection has been associated with the presence of neutralizing auto-antibodies to IFN-gamma [<a href="#rid32">32</a>] (see  <a class="medical medical_review" href="/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a>). Additionally, suppressed levels of IFN-gamma and IL-10 have been found in the stimulated whole blood of patients with NTM lung disease [<a href="#rid33">33</a>]. </p><p>TNF-alpha is produced by activated macrophages and NK cells and is also an important immune modulator for controlling mycobacterial infection. TNFa has a significant additive effect on macrophage killing of MAC [<a href="#rid34">34</a>]. The release of TNF-alpha is stimulated by and is probably responsible for the antimycobacterial effects of IFN-gamma [<a href="#rid34">34</a>]. It appears that TNF-alpha inhibitors used in the treatment of rheumatoid arthritis and other chronic inflammatory conditions may significantly exacerbate nontuberculous mycobacterial infections [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p>IL-2 greatly augments the capacity of NK cells to lyse MAC-infected monocytes. NK cells stimulated by IL-2 also enhance intracellular monocyte killing of MAC, again, likely via TNF-alpha [<a href="#rid36">36</a>]. As mentioned above, IL-12 is a major stimulant for T lymphocytes and NK cells to produce IFN-gamma and TNF-alpha. IL-12 release, in turn, is stimulated by IFN-gamma and TNF-alpha [<a href="#rid37">37,38</a>]. Granulocyte-macrophage colony stimulation factor (GM-CSF) is produced by MAC-infected monocytes and NK cells and appears to augment mycobacterial killing [<a href="#rid39">39</a>]. In contrast, IL-6 and IL-10 down-modulate the inflammatory response, especially the effect of TNF-alpha, and are therefore permissive factors for proliferation of intracellular mycobacteria [<a href="#rid40">40,41</a>]. Additionally, transforming growth factor beta (TGF-beta), which can suppress IFN-gamma, is elevated following ex vivo stimulation of blood with live <em>Mycobacterium intracellulare</em> [<a href="#rid42">42</a>].</p><p>Immune modulators act in a complicated fashion, and it is difficult to isolate and measure any single aspect of the complicated inflammatory cascade in vivo. However, understanding these processes can produce practical results as illustrated by a family with a monocyte defect in IL-12 production that was associated with disseminated MAC infection in the absence of HIV infection. This defect was overcome by exogenous administration of IFN-gamma in addition to other antimycobacterial therapy, resulting in successful treatment of the disseminated MAC infection [<a href="#rid43">43,44</a>]. Identification of specific genetic defects in the IFN-gamma and IL-12 response pathways, especially receptor deficiencies, has elucidated key pathways in immune surveillance and NTM control and identified other patients at risk for disseminated NTM infection [<a href="#rid45">45</a>]. To date, however, no specific immune deficiency has been identified for patients with NTM lung disease.</p><p class="headingAnchor" id="H784421477"><span class="h3">Evasion of the host response</span><span class="headingEndMark"> — </span>Mycobacteria have evolved mechanisms to protect themselves from the host immune response. Biofilm formation and NTM-mediated inhibition of inflammatory cytokine production are mechanisms that can subvert host immunity and promote colonization and subsequent invasion of the bronchial epithelium [<a href="#rid15">15</a>]. Components of the mycobacterial cell wall scavenge reactive oxygen intermediates, block acidification of the phagocytic vacuoles, suppress the synthesis of cytokines, and downregulate lymphocyte proliferation [<a href="#rid46">46-48</a>]. </p><p>The glycopeptidolipids (GPL) are produced by NTM but not <em>M. tuberculosis</em>. The composition and concentration of GPL vary between NTM species and can impact colony morphology. <em>M. abscessus</em>-containing nsGPL show a smooth morphotype, while those lacking nsGPL manifest as rough morphotypes. <em>M. abscessus</em> smooth variants survive in the environment and are relatively noninvasive. To deter recognition by toll-like receptor 2 (TLR2) present on innate immune cells, GPL of smooth <em>M. abscessus</em> form an outer layer that covers the mycobacterial TLR2 ligand phosphatidyl-myo-inositol mannosides, effectively preventing the glycolipid from being recognized by TLR2 [<a href="#rid49">49</a>]. The more virulent, rough morphotype emerges later, sometimes several years after the initial infection [<a href="#rid50">50</a>]. In the murine model, it was shown that human monocytes eradicated infection by smooth <em>M. abscessus</em>, whereas rough variants persisted and propagated in the intracellular phagosome [<a href="#rid51">51</a>]. Clinical and epidemiologic data also associate rough variants with more severe and persistent pulmonary disease [<a href="#rid52">52</a>]. The triggers for <em>M. abscessus</em> morphotype switching in vivo remain unknown, however, based on whole-genome analysis, switching between forms is likely an infrequent occurrence [<a href="#rid53">53</a>].</p><p><em>M. avium</em> also produces smooth and rough variants, but unlike <em>M. abscessus</em>, the transition between forms is irreversible and caused by the loss of genes involved in GPL biosynthesis [<a href="#rid54">54</a>]. Isolates with smooth-domed colony morphology are less pathogenic than those with smooth-transparent colony morphology. MAC of the smooth-domed colony types elicits greater production of inflammatory cytokines, while smooth-transparent colonial types tend to be relatively silent immunologically, causing little production of cytokines and less vigorous host responses [<a href="#rid55">55,56</a>]. While the absence of nsGPL from <em>M. abscessus</em> facilitates intracellular survival, <em>M. avium</em> ssGPL is required for intracellular survival and impacts cytokine responses, suggesting serovar oligosaccharides contribute to species-specific pathogenesis.</p><p>Biofilm formation is a successful survival strategy for environmental NTM. NTM organized in biofilms are difficult to eradicate with common decontamination practices and are resistant to standard disinfectants. Microbial pathogens found in biofilms in vivo are also very resistant to high concentrations of antimicrobial drugs. This resistance may be due to virulence enhancement in biofilms via multiple mechanisms. In one study, three rapidly growing mycobacteria (<em>Mycobacterium smegmatis</em>,<em> Mycobacterium fortuitum</em>,<em> </em>and <em>Mycobacterium chelonae</em>) were able to assemble biofilms on surfaces, and this was associated with the ability to spread on solid media [<a href="#rid57">57</a>]. Investigation into the role of biofilms in the pathogenesis and treatment of NTM disease is in an early stage, but it will likely be important, especially for improving treatment outcomes with these very treatment-refractory organisms.</p><p class="headingAnchor" id="H3924973090"><span class="h3">Host susceptibility</span><span class="headingEndMark"> — </span>Lung disease due to MAC can be differentiated into two distinct forms: fibrocavitary and nodular/bronchiectatic.</p><p class="headingAnchor" id="H4"><span class="h4">Fibrocavitary disease</span><span class="headingEndMark"> — </span>In the fibrocavitary form, upper lobe disease occurs most commonly in older male smokers with chronic pulmonary symptoms due to underlying lung disease. Symptoms and radiographic changes may be difficult to differentiate from the underlying disease, but MAC is often easily recovered from the sputum of these patients. These patients are almost universally diagnosed as a consequence of suspected tuberculosis. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H5"><span class="h4">Nodular/bronchiectatic disease</span><span class="headingEndMark"> — </span>The nodular/bronchiectatic form of MAC lung disease appears most frequently in nonsmoking women over the age of 50 who do not have a known history of underlying lung disease [<a href="#rid58">58,59</a>] but invariably have bronchiectasis at the time of NTM lung disease diagnosis. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections", section on 'Clinical manifestations'</a>.)</p><p>Body morphotype is a possible predisposition to nodular/bronchiectatic MAC lung disease. Some patients appear to have similar clinical characteristics and body types, including scoliosis, pectus excavatum, mitral valve prolapse, and joint hypermobility [<a href="#rid33">33,60-62</a>]. The constellation of phenotypic abnormalities may represent a forme fruste of a connective tissue disease hitherto unidentified and associated with NTM pulmonary disease. However, the mechanism by which this body morphotype predisposes to pulmonary mycobacterial infection is not certain. In one study, whole exome sequencing of patients with NTM lung disease found a significantly higher number of low-frequency, protein-affecting variants in immune, CFTR, cilia, and connective tissue categories compared with controls [<a href="#rid63">63</a>]. This study supports the hypothesis that the predisposition for NTM lung disease in these patients is likely due to bronchiectasis formation resulting from multi-gene abnormalities, although the exact pathways of that formation remain to be determined. Additionally, there are a number of heritable connective tissue disorders that are associated with bronchiectasis and NTM lung disease, including Marfan syndrome [<a href="#rid64">64</a>], hyper-IgE syndrome [<a href="#rid65">65</a>], and congenital contractural arachnodactyly (CCA) [<a href="#rid66">66</a>]. The identification of familial clusters of pulmonary NTM lung disease strongly supports the concept that at least some patients have NTM lung disease as a result of hereditary predispositions [<a href="#rid67">67</a>]. (See <a class="local">'Genetic predisposition'</a> below.)</p><p>There is additional evidence that some of these patients may be predisposed to NTM lung disease because of preexisting bronchiectasis. Some potential etiologies for bronchiectasis in this population include gastroesophageal reflux with chronic aspiration, alpha-1 antitrypsin deficiency, cystic fibrosis [<a href="#rid62">62,68</a>], primary ciliary dyskinesia [<a href="#rid69">69</a>], and connective tissue disorders as outlined above. Of particular interest are patients with bronchiectasis and MAC lung disease who are heterozygous for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations [<a href="#rid62">62</a>]. Single CFTR mutations appear to occur more frequently in selected populations of MAC patients with bronchiectasis. Although these patients do not meet criteria for frank cystic fibrosis, there is evidence that they have bronchial epithelial ion and water transport abnormalities that might be a mechanism for the development of bronchiectasis [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2619173983"><span class="h4">Immune defects</span><span class="headingEndMark"> — </span>Among patients without HIV infection, no severe or consistent predisposition or immune deficiency has been identified to explain susceptibility to MAC infection. Although familial clusters with NTM (mostly MAC) infections have been identified, no specific immune defect was documented [<a href="#rid67">67</a>].</p><p>One study that included patients with both cavitary and noncavitary MAC lung disease found that <em>Mycobacterium</em>-stimulated peripheral blood monocytes (PBMC) produced higher concentrations of interleukin 10 (IL-10) but lower concentrations of interferon (IFN)-gamma, IL-12, and tumor necrosis factor alpha (TNF-alpha) compared with PBMC from control subjects with a delayed hypersensitivity skin test response to <em>M. avium</em> sensitin. This suggested that IFN-gamma, TNF-alpha, and IL-12 may contribute to protection against MAC lung disease, whereas IL-10 may be immunosuppressive [<a href="#rid71">71</a>].</p><p>Another small case series noted a decreased IFN-gamma response to mitogen stimulation in five patients with MAC lung disease, and it did not improve in two patients despite successful antimycobacterial therapy [<a href="#rid72">72</a>]. A prospective study of patients with NTM nodular/bronchiectatic disease found no cytokine pathway abnormalities to explain the apparent susceptibility to MAC infection [<a href="#rid62">62</a>]. </p><p class="headingAnchor" id="H1711689158"><span class="h4">Genetic predisposition</span><span class="headingEndMark"> — </span>Research on susceptibility to NTM infection has shifted focus to potential genetic predispositions. Emerging evidence suggests that NTM pulmonary disease is a multigenic disease, in which combinations of variants across gene categories, plus environmental exposures, increase susceptibility to infection. </p><p>In a study of 69 patients with NTM lung disease and 18 unaffected family members, whole-exome sequencing identified more low-frequency, protein-affecting variants in immune, cystic fibrosis transmembrane regulator (CFTR), cilia, and connective tissue categories among the patients than among controls [<a href="#rid63">63</a>]. In a subsequent study, variant-level and gene-level parametric linkage analyses were performed on nine NTM pulmonary disease families (16 affected and 20 unaffected individuals), and a gene-level association analysis were performed on those families and 55 sporadic cases [<a href="#rid73">73</a>]. All genes on chromosome 6 were tested in the gene-level linkage analysis. The TTK protein kinase gene on chromosome 6q14.1 was the most significant association with NTM infection. The TTK gene encodes a protein kinase that is essential for mitotic check points and the DNA damage response. </p><p class="headingAnchor" id="H6"><span class="h2">Mycobacterium kansasii infection</span><span class="headingEndMark"> — </span><em>M. kansasii</em> lung disease most closely resembles typical TB in its clinical and radiographic features. Older age, male sex, smoking, and underlying lung disease are common features. Unlike most NTM, <em>M. kansasii</em> is not an environmental contaminant or colonizer (<em>M. kansasii</em>, so far, has been isolated only from municipal water supplies); thus, even a single positive culture may be considered diagnostic of disease (although diagnosis of <em>M. kansasii</em> lung disease should still be based on ATS diagnostic criteria).</p><p class="headingAnchor" id="H7"><span class="h2">Rapidly growing mycobacteria</span><span class="headingEndMark"> — </span>Rapidly growing mycobacteria, especially <em>M. abscessus</em>, also cause lung disease. In contrast to the fibrocavitary form of MAC and <em>M. kansasii</em>, affected patients tend to be females, nonsmokers, and do not have preexisting lung disease similar to patients with fibronodular MAC lung disease. In fact, <em>M. abscessus</em> is sometimes recovered from sputum of patients with MAC lung disease [<a href="#rid74">74</a>]. Noteworthy exceptions include cystic fibrosis, prior granulomatous disease, lipoid pneumonia, and esophageal dysmotility (eg, achalasia) with chronic vomiting [<a href="#rid74">74,75</a>]. As in other forms of NTM lung disease, symptoms are indolent and include cough, fever, and weight loss.</p><p class="headingAnchor" id="H8"><span class="h2">Other</span><span class="headingEndMark"> — </span><em>Mycobacterium simiae</em>, <em>Mycobacterium xenopi</em>, and <em>M. malmoense</em> have also been reported to cause chronic progressive granulomatous lung disease [<a href="#rid76">76-78</a>]. The pathogenesis of these infections, as distinct from tuberculosis and MAC lung disease, has not been elucidated, although <em>M. xenopi</em> and <em>M. malmoense</em> are associated with cigarette smoking and chronic obstructive lung disease in Europe.</p><p class="headingAnchor" id="H9"><span class="h1">DISSEMINATED DISEASE IN HIV-INFECTED PATIENTS</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria (NTM) infection in patients with HIV infection primarily presents as disseminated disease in association with very low CD4 cell counts (usually below 100 cells/microL) in resource-rich countries. Exposure has been documented from potable hot water [<a href="#rid79">79</a>]. Disseminated NTM disease occurred in 5.5 percent of acquired immunodeficiency syndrome (AIDS) cases reported to the Centers for Disease Control and Prevention (CDC) from 1981 to 1987, 96 percent of which were due to <em>M. avium</em> complex (MAC) [<a href="#rid80">80</a>]. However, effective MAC prophylaxis with <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, as well as the advent of potent antiretroviral therapy, has led to a decline in the incidence of disseminated disease. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections", section on 'Disseminated disease'</a>.)</p><p>Initial observations on disseminated MAC disease in patients with AIDS found that heavy bacteremia, widespread disease, and a high tissue burden of organisms were typical [<a href="#rid81">81</a>]. However, these reports focused on the more severe and conspicuous manifestations of this disease. More recent data have demonstrated that this illness develops progressively from bacteremia arising from initially localized infection, especially from a respiratory or gastrointestinal source [<a href="#rid82">82-85</a>]. In one large series, among AIDS patients with CD4 lymphocytes &lt;50/mL, nearly 60 percent of those with respiratory or fecal MAC developed MAC bacteremia within one year [<a href="#rid82">82</a>]. The risk of MAC bacteremia was increased 2.3-fold for patients with respiratory MAC and 6.0-fold for patients with fecal MAC compared to those without respiratory or fecal MAC, respectively. Patients may be infected simultaneously with two different strains of MAC and these strains may have different susceptibility patterns [<a href="#rid86">86</a>]. </p><p>At first, bacteremia from these localized infections may be infrequent and intermittent. In patients followed with serial blood cultures through death and postmortem examination, the tissue burden of organisms and the number of tissues involved increased in direct proportion to the time after the initial positive blood cultures and to the fraction of blood cultures that were positive [<a href="#rid83">83</a>]. Disseminated MAC in AIDS is very rare in countries in which tuberculosis is endemic, despite the presence of MAC in the environment and skin test evidence of MAC exposure in these regions. These observations suggest a role for cross-protective immunity from childhood BCG and/or latent TB [<a href="#rid87">87,88</a>].</p><p>Thus, the pathogenetic model proposes that mycobacteria from the environment infect a mucosal surface (gut or lung), multiply locally, and eventually enter the bloodstream and disseminate, seeding other organs and tissues [<a href="#rid84">84,85</a>]. As metastatic foci of infection progress, bacteremia becomes more constant and heavier, and tissue involvement increases.</p><p class="headingAnchor" id="H8892280"><span class="h1">LYMPHADENITIS</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria (NTM) can cause lymphadenitis, primarily in children younger than five years of age. The frequent involvement of cervical lymph nodes suggests that ingestion and direct tissue penetration by the organism is the usual pathogenesis of this disease. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/86045.html" rel="external">"Nontuberculous mycobacterial lymphadenitis in children"</a>.)</p><p class="headingAnchor" id="H1642373090"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Mycobacteria, other than <em>Mycobacterium tuberculosis</em> and <em>Mycobacterium leprae</em>, are generally free-living organisms that are ubiquitous in the environment (<a class="graphic graphic_table graphicRef61936" href="/d/graphic/61936.html" rel="external">table 1</a>). They have been recovered from surface water, tap water, soil, domestic and wild animals, milk, and food products. Although nontuberculous mycobacteria (NTM) can inhabit body surfaces and secretions without causing disease, they can, in broad terms, induce four distinct clinical syndromes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary disease is usually associated with bronchiectasis or chronic obstructive lung disease and caused primarily by <em>Mycobacterium avium</em> complex (MAC) <em>Mycobacterium kansasii</em> and <em>Mycobacterium abscessus</em>, especially in older persons.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Superficial lymphadenitis, especially cervical lymphadenitis, in children is caused mostly by MAC, <em>Mycobacterium scrofulaceum</em>, and, in northern Europe, <em>Mycobacterium malmoense</em> (<em>M. tuberculosis</em> is a more common cause of lymphadenitis in tuberculosis-endemic countries).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disseminated disease can occur in severely immunocompromised patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin and soft tissue infection usually is a consequence of direct inoculation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary infection with NTM is probably acquired by inhalation; most likely aerosols from natural surface water or from domestic and institutional hot water systems. (See <a class="local">'Pulmonary infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The observation that pulmonary MAC disease is relatively rare, despite the high prevalence of skin test reactivity to MAC in young adulthood, suggests that the host immune response is highly effective at containing or eliminating the infecting microbes. If inhaled MAC survive their initial encounter with alveolar macrophages, blood-borne host defenses are called into play, most importantly lymphocytes and monocytes that differentiate into macrophages. MAC is taken up by macrophages and survives and proliferates within vacuoles in their cytoplasm as an intracellular pathogen. (See <a class="local">'Mycobacterium avium complex'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocytes ultimately interact with the infected macrophages to induce intracellular destruction of the mycobacteria or to destroy the infected macrophage itself. T helper lymphocytes are the basis of acquired (antigen-specific) immunity, while natural killer (NK) cells are key components of the innate immune response to these pathogens. This interaction between macrophage, lymphocyte, and microbe is the focal point in the pathogenesis and immunology of MAC infection that leads to granuloma formation, successful control of the infection, or clinical disease. This chain of events is similar to those described for tuberculosis. (See <a class="local">'Mycobacterium avium complex'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NTM infection in patients with AIDS primarily presents as disseminated disease in association with very low CD4 lymphocyte counts (usually below 100/microL). In such patients, mycobacteria from the environment infect a mucosal surface (gut or lung), multiply locally, and eventually enter the bloodstream and disseminate, seeding other organs and tissues. As metastatic foci of infection progress, bacteremia becomes more constant and heavier, and tissue involvement increases. (See <a class="local">'Disseminated disease in HIV-infected patients'</a> above.) </p><p></p><p class="bulletIndent1">Disseminated NTM disease is also seen in patients with rare genetic defects that alter IL-12 and IFN-gamma production and in association with TNF-alpha inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NTM can cause lymphadenitis, primarily in children younger than five years of age. The frequent involvement of cervical lymph nodes suggests that ingestion and direct tissue penetration by the organism is the usual pathogenesis of this disease. (See <a class="local">'Lymphadenitis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007; 131:1166.</a></li><li><a class="nounderline abstract_t">Kim Y, Yoon JH, Ryu J, et al. Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease. Chest 2023; 163:270.</a></li><li><a class="nounderline abstract_t">Good RC, Snider DE Jr. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146:829.</a></li><li><a class="nounderline abstract_t">CORPE RF, STERGUS I. Is the histopathology of nonphotochromogenic mycobacterial infections distinguishable from that caused by Mycobacterium tuberculosis? Am Rev Respir Dis 1963; 87:289.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5:1122.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Young LS, Enkel H. Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun 1991; 59:1697.</a></li><li><a class="nounderline abstract_t">Roecklein JA, Swartz RP, Yeager H Jr. Nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages. J Lab Clin Med 1992; 119:772.</a></li><li><a class="nounderline abstract_t">Swartz RP, Naai D, Vogel CW, Yeager H Jr. Differences in uptake of mycobacteria by human monocytes: a role for complement. Infect Immun 1988; 56:2223.</a></li><li><a class="nounderline abstract_t">Holland SM. Host defense against nontuberculous mycobacterial infections. Semin Respir Infect 1996; 11:217.</a></li><li><a class="nounderline abstract_t">Ogata K, Linzer BA, Zuberi RI, et al. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992; 60:4720.</a></li><li><a class="nounderline abstract_t">Hayashi T, Catanzaro A, Rao SP. Apoptosis of human monocytes and macrophages by Mycobacterium avium sonicate. Infect Immun 1997; 65:5262.</a></li><li><a class="nounderline abstract_t">Klingler K, Tchou-Wong KM, Brändli O, et al. Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Infect Immun 1997; 65:5272.</a></li><li><a class="nounderline abstract_t">Honda JR, Knight V, Chan ED. Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin Chest Med 2015; 36:1.</a></li><li><a class="nounderline abstract_t">Rose SJ, Bermudez LE. Mycobacterium avium biofilm attenuates mononuclear phagocyte function by triggering hyperstimulation and apoptosis during early infection. Infect Immun 2014; 82:405.</a></li><li><a class="nounderline abstract_t">McGarvey J, Bermudez LE. Pathogenesis of nontuberculous mycobacteria infections. Clin Chest Med 2002; 23:569.</a></li><li><a class="nounderline abstract_t">Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell 1995; 82:697.</a></li><li class="breakAll">Dannenberg AM Jr, Rook GAW. Pathogenesis of pulmonary tuberculosis: An interplay of tissue-damaging and macrophage-activating immune responses — dual mechanisms that control bacillary multiplications. In: Tuberculosis: Pathogenesis, Protection, and Control, Bloom BR (Ed), ASM Press, Washington, DC 1994. p.459.</li><li><a class="nounderline abstract_t">Regev D, Surolia R, Karki S, et al. Heme oxygenase-1 promotes granuloma development and protects against dissemination of mycobacteria. Lab Invest 2012; 92:1541.</a></li><li><a class="nounderline abstract_t">O'Connell ML, Birkenkamp KE, Kleiner DE, et al. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest 2012; 141:1203.</a></li><li><a class="nounderline abstract_t">Malcolm KC, Nichols EM, Caceres SM, et al. Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival. PLoS One 2013; 8:e57402.</a></li><li><a class="nounderline abstract_t">Fulton SA, Johnsen JM, Wolf SF, et al. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis. Infect Immun 1996; 64:2523.</a></li><li><a class="nounderline abstract_t">Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16:495.</a></li><li><a class="nounderline abstract_t">Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999; 238:57.</a></li><li><a class="nounderline abstract_t">Blanchard DK, Michelini-Norris MB, Friedman H, Djeu JY. Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: role of LFA-1. Cell Immunol 1989; 119:402.</a></li><li><a class="nounderline abstract_t">Katz P, Yeager H Jr, Whalen G, et al. Natural killer cell-mediated lysis of Mycobacterium-avium complex-infected monocytes. J Clin Immunol 1990; 10:71.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Young LS. Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex. Microb Pathog 1989; 7:289.</a></li><li><a class="nounderline abstract_t">Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749.</a></li><li><a class="nounderline abstract_t">Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123:216.</a></li><li><a class="nounderline abstract_t">Darnell JE Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998; 18:549.</a></li><li><a class="nounderline abstract_t">Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11:321.</a></li><li><a class="nounderline abstract_t">van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004; 4:739.</a></li><li><a class="nounderline abstract_t">Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.</a></li><li><a class="nounderline abstract_t">Kartalija M, Ovrutsky AR, Bryan CL, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013; 187:197.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140:3006.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Yamashita S, Beekmann SE, et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Young LS. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J Immunol 1991; 146:265.</a></li><li><a class="nounderline abstract_t">Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181:1615.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 1995; 63:4099.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Martinelli J, Petrofsky M, et al. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis 1994; 169:575.</a></li><li><a class="nounderline abstract_t">Denis M. Interleukin-6 is used as a growth factor by virulent Mycobacterium avium: presence of specific receptors. Cell Immunol 1992; 141:182.</a></li><li><a class="nounderline abstract_t">Bermudez LE, Champsi J. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993; 61:3093.</a></li><li><a class="nounderline abstract_t">Ovrutsky AR, Merkel PA, Schonteich E, et al. Patients with non-tuberculous mycobacterial lung disease have elevated transforming growth factor-beta following ex vivo stimulation of blood with live Mycobacterium intracellulare. Scand J Infect Dis 2013; 45:711.</a></li><li><a class="nounderline abstract_t">Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994; 330:1348.</a></li><li><a class="nounderline abstract_t">Frucht DM, Holland SM. Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J Immunol 1996; 157:411.</a></li><li><a class="nounderline abstract_t">Guide SV, Holland SM. Host susceptibility factors in mycobacterial infection. Genetics and body morphotype. Infect Dis Clin North Am 2002; 16:163.</a></li><li><a class="nounderline abstract_t">Chan J, Fan XD, Hunter SW, et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991; 59:1755.</a></li><li><a class="nounderline abstract_t">Hines ME 2nd, Jaynes JM, Barker SA, et al. Isolation and partial characterization of glycolipid fractions from Mycobacterium avium serovar 2 (Mycobacterium paratuberculosis 18) that inhibit activated macrophages. Infect Immun 1993; 61:1.</a></li><li><a class="nounderline abstract_t">Tsuyuguchi I, Kawasumi H, Takashima T, et al. Mycobacterium avium-Mycobacterium intracellular complex-induced suppression of T-cell proliferation in vitro by regulation of monocyte accessory cell activity. Infect Immun 1990; 58:1369.</a></li><li><a class="nounderline abstract_t">Rhoades ER, Archambault AS, Greendyke R, et al. Mycobacterium abscessus Glycopeptidolipids mask underlying cell wall phosphatidyl-myo-inositol mannosides blocking induction of human macrophage TNF-alpha by preventing interaction with TLR2. J Immunol 2009; 183:1997.</a></li><li><a class="nounderline abstract_t">Catherinot E, Roux AL, Macheras E, et al. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 2009; 47:271.</a></li><li><a class="nounderline abstract_t">Byrd TF, Lyons CR. Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect Immun 1999; 67:4700.</a></li><li><a class="nounderline abstract_t">Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39:816.</a></li><li><a class="nounderline abstract_t">Pawlik A, Garnier G, Orgeur M, et al. Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus. Mol Microbiol 2013; 90:612.</a></li><li><a class="nounderline abstract_t">Pang L, Tian X, Pan W, Xie J. Structure and function of mycobacterium glycopeptidolipids from comparative genomics perspective. J Cell Biochem 2013; 114:1705.</a></li><li><a class="nounderline abstract_t">Shiratsuchi H, Toossi Z, Mettler MA, Ellner JJ. Colonial morphotype as a determinant of cytokine expression by human monocytes infected with Mycobacterium avium. J Immunol 1993; 150:2945.</a></li><li><a class="nounderline abstract_t">Michelini-Norris MB, Blanchard DK, Pearson CA, Djeu JY. Differential release of interleukin (IL)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of Mycobacterium avium-intracellulare complex. J Infect Dis 1992; 165:702.</a></li><li><a class="nounderline abstract_t">Sousa S, Bandeira M, Carvalho PA, et al. Nontuberculous mycobacteria pathogenesis and biofilm assembly. Int J Mycobacteriol 2015; 4:36.</a></li><li><a class="nounderline abstract_t">Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863.</a></li><li><a class="nounderline abstract_t">Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101:1605.</a></li><li><a class="nounderline abstract_t">Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999; 115:1033.</a></li><li><a class="nounderline abstract_t">Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1991; 144:914.</a></li><li><a class="nounderline abstract_t">Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066.</a></li><li><a class="nounderline abstract_t">Szymanski EP, Leung JM, Fowler CJ, et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. Am J Respir Crit Care Med 2015; 192:618.</a></li><li><a class="nounderline abstract_t">Gelb BD. Marfan's syndrome and related disorders--more tightly connected than we thought. N Engl J Med 2006; 355:841.</a></li><li><a class="nounderline abstract_t">Melia E, Freeman AF, Shea YR, et al. Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. J Allergy Clin Immunol 2009; 124:617.</a></li><li><a class="nounderline abstract_t">Paulson ML, Olivier KN, Holland SM. Pulmonary non-tuberculous mycobacterial infection in congenital contractural arachnodactyly. Int J Tuberc Lung Dis 2012; 16:561.</a></li><li><a class="nounderline abstract_t">Colombo RE, Hill SC, Claypool RJ, et al. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010; 137:629.</a></li><li><a class="nounderline abstract_t">Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006; 130:995.</a></li><li><a class="nounderline abstract_t">Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013; 188:913.</a></li><li><a class="nounderline abstract_t">Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181:1078.</a></li><li><a class="nounderline abstract_t">Vankayalapati R, Wizel B, Samten B, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J Infect Dis 2001; 183:478.</a></li><li><a class="nounderline abstract_t">Safdar A, White DA, Stover D, et al. Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 2002; 113:756.</a></li><li><a class="nounderline abstract_t">Chen F, Szymanski EP, Olivier KN, et al. Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, TTK, for Pulmonary Nontuberculous Mycobacterial Disease. Am J Respir Crit Care Med 2017; 196:1599.</a></li><li><a class="nounderline abstract_t">Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae. Clin Chest Med 1989; 10:419.</a></li><li><a class="nounderline abstract_t">Alberts WM, Chandler KW, Solomon DA, Goldman AL. Pulmonary disease caused by Mycobacterium malmoense. Am Rev Respir Dis 1987; 135:1375.</a></li><li><a class="nounderline abstract_t">Costrini AM, Mahler DA, Gross WM, et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981; 123:104.</a></li><li><a class="nounderline abstract_t">Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 1992; 5:1.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Maslow JN, Barber TW, et al. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994; 343:1137.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4.</a></li><li><a class="nounderline abstract_t">Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165:1082.</a></li><li><a class="nounderline abstract_t">Chin DP, Hopewell PC, Yajko DM, et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169:289.</a></li><li><a class="nounderline abstract_t">Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991; 164:994.</a></li><li><a class="nounderline abstract_t">Torriani FJ, McCutchan JA, Bozzette SA, et al. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994; 170:1601.</a></li><li><a class="nounderline abstract_t">Torriani FJ, Behling CA, McCutchan JA, et al. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis 1996; 173:942.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Jacobs NJ, Arbeit RD, et al. Polyclonal Mycobacterium avium infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of M. avium isolated from the same patient. J Clin Microbiol 1995; 33:1008.</a></li><li><a class="nounderline abstract_t">Fordham von Reyn C, Arbeit RD, Tosteson AN, et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group. AIDS 1996; 10:1025.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Barber TW, Arbeit RD, et al. Evidence of previous infection with Mycobacterium avium-Mycobacterium intracellulare complex among healthy subjects: an international study of dominant mycobacterial skin test reactions. J Infect Dis 1993; 168:1553.</a></li></ol></div><div id="topicVersionRevision">Topic 5345 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426224" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36087796" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6815283" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Isolation of nontuberculous mycobacteria in the United States, 1980.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14023125" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Is the histopathology of nonphotochromogenic mycobacterial infections distinguishable from that caused by Mycobacterium tuberculosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11769770" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1826895" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593222" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3137162" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Differences in uptake of mycobacteria by human monocytes: a role for complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8976576" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Host defense against nontuberculous mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1398982" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393825" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Apoptosis of human monocytes and macrophages by Mycobacterium avium sonicate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393826" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676515" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pathogenesis and risk factors for nontuberculous mycobacterial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24191301" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mycobacterium avium biofilm attenuates mononuclear phagocyte function by triggering hyperstimulation and apoptosis during early infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370993" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathogenesis of nontuberculous mycobacteria infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671299" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Natural killer cell receptors: the offs and ons of NK cell recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671299" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Natural killer cell receptors: the offs and ons of NK cell recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964851" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Heme oxygenase-1 promotes granuloma development and protects against dissemination of mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22194586" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23451220" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698475" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9597139" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10087650" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Interleukin-12: basic principles and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649255" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: role of LFA-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312668" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Natural killer cell-mediated lysis of Mycobacterium-avium complex-infected monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2560109" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9143706" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cellular responses to interferon-gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598304" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interferon-gamma in the management of infectious diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726434" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959079" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interferon-gamma and interleukin-12 pathway defects and human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15567123" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913682" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adult-onset immunodeficiency in Thailand and Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144328" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2834450" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419421" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898601" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722441" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7558325" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158029" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555250" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Interleukin-6 is used as a growth factor by virulent Mycobacterium avium: presence of specific receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8514420" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23808720" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Patients with non-tuberculous mycobacterial lung disease have elevated transforming growth factor-beta following ex vivo stimulation of blood with live Mycobacterium intracellulare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7908719" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8683146" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11917812" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Host susceptibility factors in mycobacterial infection. Genetics and body morphotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1850379" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418031" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Isolation and partial characterization of glycolipid fractions from Mycobacterium avium serovar 2 (Mycobacterium paratuberculosis 18) that inhibit activated macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691144" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mycobacterium avium-Mycobacterium intracellular complex-induced suppression of T-cell proliferation in vitro by regulation of monocyte accessory cell activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596998" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mycobacterium abscessus Glycopeptidolipids mask underlying cell wall phosphatidyl-myo-inositol mannosides blocking induction of human macrophage TNF-alpha by preventing interaction with TLR2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020061" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute respiratory failure involving an R variant of Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10456919" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158161" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23998761" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23444081" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Structure and function of mycobacterium glycopeptidolipids from comparative genomics perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8454866" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Colonial morphotype as a determinant of cytokine expression by human monocytes infected with Mycobacterium avium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552199" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Differential release of interleukin (IL)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of Mycobacterium avium-intracellulare complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26655196" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Nontuberculous mycobacteria pathogenesis and biofilm assembly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2770822" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Infection with Mycobacterium avium complex in patients without predisposing conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600780" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208205" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928970" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703788" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26038974" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929000" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Marfan's syndrome and related disorders--more tightly connected than we thought.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19733303" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325249" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pulmonary non-tuberculous mycobacterial infection in congenital contractural arachnodactyly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858235" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Familial clustering of pulmonary nontuberculous mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035430" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796196" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167849" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133380" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517367" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28777004" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, TTK, for Pulmonary Nontuberculous Mycobacterial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8484642" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2673650" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, M. fortuitum and M. chelonae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3592410" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pulmonary disease caused by Mycobacterium malmoense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7458072" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735092" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Agents of newly recognized or infrequently encountered mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910236" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912355" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349906" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906290" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1682396" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Natural history of disseminated Mycobacterium avium complex infection in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996004" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603975" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Disseminated Mycobacterium avium complex: correlation between blood and tissue burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7790424" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Polyclonal Mycobacterium avium infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of M. avium isolated from the same patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8853737" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245545" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Evidence of previous infection with Mycobacterium avium-Mycobacterium intracellulare complex among healthy subjects: an international study of dominant mycobacterial skin test reactions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
